We could not find any results for:
Make sure your spelling is correct or try broadening your search.
CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics...
CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics...
– exoASO-STAT6 demonstrated durable pharmacokinetic/pharmacodynamic profile in preclinical models; biomarkers with clinical translational potential identified, providing a rationale for selecting...
– Patient enrollment continuing in Phase 1 clinical trial of exoASO™-STAT6 in patients with advanced hepatocellular carcinoma; preliminary data anticipated during 1H 2023 – – Presented preclinical...
– Data support advancement of Codiak’s engineered exosome bivalent vaccine candidate toward IND-enabling studies – CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc...
– Data to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting – CAMBRIDGE, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a...
CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a clinical-stage biopharmaceutical company pioneering the development of exosome-based...
CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a clinical-stage biopharmaceutical company pioneering the development of exosome-based...
– Enrollment continues in Phase 1 clinical trial of IV-administered exoASO™-STAT6 in patients with advanced hepatocellular carcinoma – – Prioritizing vaccine program funded by...
– Reported platform-validating initial data from Phase 1 studies of exoSTING™ and exoIL-12™; plans to initiate Phase 2 studies for both programs in 1H 2023 – – Initiated patient dosing in Phase 1...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0.057 | 0.057 | 0.057 | 0 | 0 | CS |
4 | 0 | 0 | 0.057 | 0.057 | 0.057 | 0 | 0 | CS |
12 | 0 | 0 | 0.057 | 0.057 | 0.057 | 0 | 0 | CS |
26 | 0 | 0 | 0.057 | 0.057 | 0.057 | 0 | 0 | CS |
52 | 0 | 0 | 0.057 | 0.057 | 0.057 | 0 | 0 | CS |
156 | -18.993 | -99.7007874016 | 19.05 | 19.61 | 0.0532 | 198734 | 1.56769128 | CS |
260 | -14.043 | -99.5957446809 | 14.1 | 37.85 | 0.0532 | 196640 | 5.29311167 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions